Dimethyl fumarate: the new tableted preparation for the treatment of multiple sclerosis

Dimethyl fumarate (DMF) is dimethyl ester of fumaric acid, a naturally occurring molecule that plays a key role in redox processes of tissue respiration. Results of studies on animal models demonstrate that the drug has an anti-inflammatory and cytoprotective action. Anti-inflammatory effects of DMF could be mediated by several mechanisms, including inhibition of nuclear factor-kappaB-dependent transcription and suppression of cytokine production and cell adhesion molecule expression. 2 years after start of treatment DMF significantly increased the relative number of patients without active disease by clinical, radiological and general criteria in comparison with the placebo group. According to the DEFINE trial, the proportion of patients without active disease in twice daily DMF group was 28% (vs placebo, p = 0,012), and 18% (vs placebo, p < 0, 0001) according to the CONFIRM trial. DMF demonstrated similar efficacy in various subgroups of patients classified according to baseline characteristics of the disease, including frequency of relapses in the past, pre-treatment, level of disability, as well as type and extent of the lesions. In terms of safety profile, DMF was similar to GA and placebo. Adverse effects on the gastrointestinal tract against the background of DMF were mild or moderate, transient and treatable. Administration of DMF did not increase the risk of infections and malignancies.

рассеянный склероз, диметилфумарат нейродегенерация, оксидативный стресс, цитопротективный эффект, multiple sclerosis, dimethyl fumarate, neurodegeneration, oxidative stress, cytoprotective effect

1. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroin-flammation via activation of the Nrf2 antioxidant pathway. Brain, 2011. 134: 678-92.

2. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxi-dant therapy. J Neurol, 2004. 251: 261-8.

3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med, 2000. 343: 938-52.

4. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbated experimental autoimmune encephalomyelitis. Toxicol Sci, 2010. 114: 237-46.

5. Dawson K et al. Представлено на CMSC; 27-30 мая 2009 г., Атланта, штат Джорджия, США. S71.

6. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol, 2007 May. 156(5): 838-42.

7. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethyl-fumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol, 2001 Jun. 144(6): 1114-20.

8. Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M. Dimethyl Fumarate Suppresses Inflammation In Vitro via Both Nrf2-dependent and Nrf2-independent Pathways. 64th Annual Meeting of the American Academy of Neurology, April 21-28, New Orleans, USA. P02.108. 2012.

9. Loewe R, Pillinger M, de Martin R, Mrowietz U, Groger M, Holnthoner W, et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol, 2001 Dec. 117(6): 1363-8.

10. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol, 2006 Jul. 145(1): 101-7.

11. Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol, 2005 Sep. 166(1-2): 132-43.

12. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immu-nomodulation. J Neuroinflammation, 2012. 9: 163.

13. Arnold H, Huang C, Huang R, Engber T, Yamamoto M, Rhodes K, et al. The Neuroprotective Effects of BG-12 (Dimethyl Fumarate) on Malonate-induced Striatal Lesion Volume are Dependent upon Nrf2. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 10-13 October, Lyon, France. P962. 2012.

14. Lee DH, Gold R, Linker RA. Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. Int J Mol Sci, 2012. 13(9): 11783-803.

15. Scannevin R, Huang C, Engber T, Rhodes K, Arnold H. Neuroprotective Effects of BG-12 on Malonate-induced Striatal Lesion Volume in Sprague-Dawley Rat Brain Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis. May 30-June 2. San Diego, CA, USA. 2012.

16. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol., 2006 May. 290(5): H1862-70.